132 related articles for article (PubMed ID: 30824610)
1. Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer.
Kitagawa K; Gonoi R; Tatsumi M; Kadowaki M; Katayama T; Hashii Y; Fujisawa M; Shirakawa T
Mol Cancer Ther; 2019 May; 18(5):980-990. PubMed ID: 30824610
[TBL] [Abstract][Full Text] [Related]
2. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
Kitagawa K; Oda T; Saito H; Araki A; Gonoi R; Shigemura K; Hashii Y; Katayama T; Fujisawa M; Shirakawa T
Cancer Immunol Immunother; 2017 Jun; 66(6):787-798. PubMed ID: 28299466
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.
Minagawa H; Hashii Y; Nakajima H; Fujiki F; Morimoto S; Nakata J; Shirakawa T; Katayama T; Tsuboi A; Ozono K
BMC Cancer; 2023 Feb; 23(1):167. PubMed ID: 36803483
[TBL] [Abstract][Full Text] [Related]
4. An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia.
Nakagawa N; Hashii Y; Kayama H; Okumura R; Nakajima H; Minagawa H; Morimoto S; Fujiki F; Nakata J; Shirakawa T; Katayama T; Takeda K; Tsuboi A; Ozono K
Cancer Immunol Immunother; 2023 Jan; 72(1):39-53. PubMed ID: 35699757
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.
Shirakawa T; Kitagawa K
Hum Vaccin Immunother; 2018 Jan; 14(1):159-162. PubMed ID: 29048978
[TBL] [Abstract][Full Text] [Related]
6. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.
Ueki H; Kitagawa K; Kato M; Yanase S; Okamura Y; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M; Shirakawa T
Sci Rep; 2023 Jun; 13(1):9994. PubMed ID: 37340017
[TBL] [Abstract][Full Text] [Related]
7. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
[TBL] [Abstract][Full Text] [Related]
8. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice.
Kitagawa K; Omoto C; Oda T; Araki A; Saito H; Shigemura K; Katayama T; Hotta H; Shirakawa T
Viral Immunol; 2017 Apr; 30(3):196-203. PubMed ID: 28112593
[TBL] [Abstract][Full Text] [Related]
9. Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice.
Babiarova K; Kutinova L; Zurkova K; Krystofova J; Brabcova E; Hainz P; Musil J; Nemeckova S
J Immunother; 2012 Jul; 35(6):478-87. PubMed ID: 22735806
[TBL] [Abstract][Full Text] [Related]
10. An oral cancer vaccine using a
Kitagawa K; Tatsumi M; Kato M; Komai S; Doi H; Hashii Y; Katayama T; Fujisawa M; Shirakawa T
Mol Ther Oncolytics; 2021 Sep; 22():592-603. PubMed ID: 34589578
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo.
Yoneda T; Kunimura N; Kitagawa K; Fukui Y; Saito H; Narikiyo K; Ishiko M; Otsuki N; Nibu KI; Fujisawa M; Serada S; Naka T; Shirakawa T
Cancer Gene Ther; 2019 Nov; 26(11-12):388-399. PubMed ID: 30607005
[TBL] [Abstract][Full Text] [Related]
12. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice.
Eslami NS; Shokrgozar MA; Mousavi A; Azadmanesh K; Nomani A; Apostolopoulos V; Day S; Amanzadeh A; Alimohammadian MH
Mol Immunol; 2012 Jul; 51(3-4):325-31. PubMed ID: 22525006
[TBL] [Abstract][Full Text] [Related]
14. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
Gaiger A; Reese V; Disis ML; Cheever MA
Blood; 2000 Aug; 96(4):1480-9. PubMed ID: 10942395
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.
Cole G; Ali AA; McErlean E; Mulholland EJ; Short A; McCrudden CM; McCaffrey J; Robson T; Kett VL; Coulter JA; Dunne NJ; Donnelly RF; McCarthy HO
Acta Biomater; 2019 Sep; 96():480-490. PubMed ID: 31299353
[TBL] [Abstract][Full Text] [Related]
16. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
17. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
[TBL] [Abstract][Full Text] [Related]
18. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
19. WT1 as a novel target antigen for cancer immunotherapy.
Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
